• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Medicare Budget Pinched By Payments for the Departed

Article

An investigation into 2012 Medicare claims for HIV-infected patients unearthed payment for prescriptions that were filled up to 32 days after the patient's passing.

Call it drugs for the departed: Medicare's prescription program kept paying for costly medications even after patients were dead.

The problem was traced back to a head-scratching bureaucratic rule that's now getting a second look.

A report coming out Friday from the Health and Human Services Department's inspector general says the Medicare rule allows payment for prescriptions filled up to 32 days after a patient's death — at odds with the program's basic principles, not to mention common sense.

"Drugs for deceased beneficiaries are clearly not medically indicated, which is a requirement for (Medicare) coverage," the IG report said. It urged immediate changes to eliminate or restrict the payment policy. Medicare said it's working on a fix.

Investigators examined claims from 2012 for a tiny sliver of Medicare drugs — medications to treat HIV, the virus that causes AIDS — and then cross-referenced them with death records. They found that the program paid for drugs for 158 beneficiaries after they were already dead. The cost to taxpayers: $292,381, an average of $1,850 for each beneficiary.

Medicare's "current practices allowed most of these payments to occur," the report said.

Complete report on abcNews: http://abcn.ws/1u0NPUN

Related Videos
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Patrick Sullivan, DVM, PhD
Dr Brian Mulherin
Dr Brian Mulherin
Lindsey Valenzuela, PharmD, APh, BCACP - screenshot by AJMC
Robert Andrews, former US representative for New Jersey and CEO of the Health Transformation Alliance
Robert Andrews, chief executive officer, Health Transformation Alliance
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.